If you’re looking forward to tuning into the 2026 Masters and wondering what transpired at the first major championship last year, let us be the first to tell you that the 2025 edition of the Masters ...

New tax deductions for overtime pay, tips, seniors, and car loan interest don’t disappear immediately when income crosses a line. Some deductions, such as one for those 65 and older, end up being ...

$0 to $10,275. $0 to $20,550. $0 to $10,275. $0 to $14,650. $10,276 to $41,775. $20,551 to $83,550. $10,276 to $41,775. $14,651 to $55,900. $41,776 to $89,075 ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Project 2025, a conservative think tank’s blueprint to reshape the ...

Tax season is approaching, and millions of Americans will soon turn their attention to tax brackets. Every year, the Internal Revenue Service announces new tax brackets, tiers of income that are taxed ...

Attribution researches the influence of climate change on local weather and impacts. We issues alerts in many instances when the Climate Shift Index identifies a notable extreme weather event around ...

Stock exchange-traded funds, or equity ETFs, are often low-cost, tax-efficient instruments for investors to track popular indexes or leverage experienced manager choices to beat the market. The best ...

While it would be presumptuous to base conclusions solely on the number of drugs the FDA approved in 2025, it is noteworthy that FDA nods of new treatments fell short of previous years, though a surge ...

The Morningstar US Large-Mid Cap Index rose 17.71% in 2025. The large-mid index tracks the performance of the top 90% of the US investable universe by market cap, and each year we screen from among ...

As 2025 comes to a close, people turn to the highlights of what made the year special…or at least bearable. There were plenty of viral trends and memes that took over the internet this year, though ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S. research enterprise has been scrambled by a series of political decisions ...